|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tempero MA, Malafa MP, Behrman SW, Benson
AB III, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B,
Engebretson A, et al: Pancreatic adenocarcinoma, version 2.2014:
Featured updates to the NCCN guidelines. J Natl Compr Canc Netw.
12:1083–1093. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Inoki K, Zhu T and Guan KL: TSC2 mediates
cellular energy response to control cell growth and survival. Cell.
115:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Madiraju AK, Erion DM, Rahimi Y, Zhang XM,
Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald
MJ, et al: Metformin suppresses gluconeogenesis by inhibiting
mitochondrial glycerophosphate dehydrogenase. Nature. 510:542–546.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Del Barco S, Vazquez-Martin A, Cufí S,
Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B
and Menendez JA: Metformin: Multi-faceted protection against
cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ben Sahra I, Le Marchand-Brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: A new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jalving M, Gietema JA, Lefrandt JD, de
Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: Taking away
the candy for cancer? Eur J Cancer. 46:2369–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo Q, Hu D, Hu S, Yan M, Sun Z and Chen
F: In vitro and in vivo anti-tumor effect of metformin as a novel
therapeutic agent in human oral squamous cell carcinoma. BMC
Cancer. 12:5172012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang P, Li H, Tan X, Chen L and Wang S:
Association of metformin use with cancer incidence and mortality: A
meta-analysis. Cancer Epidemiol. 37:207–218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang ZJ and Li S: The prognostic value of
metformin for cancer patients with concurrent diabetes: A
systematic review and meta-analysis. Diabetes Obes Metab.
16:707–710. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yin M, Zhou J, Gorak EJ and Quddus F:
Metformin is associated with survival benefit in cancer patients
with concurrent type 2 diabetes: A systematic review and
meta-analysis. Oncologist. 18:1248–1255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meng F, Song L and Wang W: Metformin
improves overall survival of colorectal cancer patients with
diabetes: A meta-analysis. J Diabetes Res. 2017:50632392017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D,
Xie J, Tao M and Mao Y: Metformin use is associated with better
survival of breast cancer patients with diabetes: A meta-analysis.
Oncologist. 20:1236–1244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang YL, Zhu LY, Li Y, Yu J, Wang J, Zeng
XX, Hu KX, Liu JY and Xu JX: Metformin use is associated with
reduced incidence and improved survival of endometrial cancer: A
meta-analysis. BioMed Res Int. 2017:59053842017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deng D, Yang Y, Tang X, Skrip L, Qiu J,
Wang Y and Zhang F: Association between metformin therapy and
incidence, recurrence and mortality of prostate cancer: Evidence
from a meta-analysis. Diabetes Metab Res Rev. 31:595–602. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee SH, Yoon SH, Lee HS, Chung MJ, Park
JY, Park SW, Song SY, Chung JB and Bang S: Can metformin change the
prognosis of pancreatic cancer? Retrospective study for pancreatic
cancer patients with pre-existing diabetes mellitus type 2. Dig
Liver Dis. 48:435–440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hwang AL, Haynes K, Hwang WT and Yang YX:
Metformin and survival in pancreatic cancer: A retrospective cohort
study. Pancreas. 42:1054–1059. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reni M, Dugnani E, Cereda S, Belli C,
Balzano G, Nicoletti R, Liberati D, Pasquale V, Scavini M, Maggiora
P, et al: (Ir)relevance of metformin treatment in patients with
metastatic pancreatic cancer: An open-label, randomized phase II
trial. Clin Cancer Res. 22:1076–1085. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kordes S, Pollak MN, Zwinderman AH, Mathôt
RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ and Wilmink JW:
Metformin in patients with advanced pancreatic cancer: A
double-blind, randomised, placebo-controlled phase 2 trial. Lancet
Oncol. 16:839–847. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. Int J Surg. 8:336–341.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
von Elm E, Altman DG, Egger M, Pocock SJ,
Gøtzsche PC and Vandenbroucke JP: STROBE Initiative: The
strengthening the reporting of observational studies in
epidemiology (STROBE) statement: Guidelines for reporting
observational studies. J Clin Epidemiol. 61:344–349. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Higgins JPT: GSe: Cochrane handbook for
systematic reviews of interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration available from. https://www.cochrane-handbook.orgMarch 2–2016
|
|
23
|
Wells GA, Shea B, O'Connell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of non-randomized studies in
meta-analysis. 2000.
|
|
24
|
van Houwelingen HC, Arends LR and Stijnen
T: Advanced methods in meta-analysis: Multivariate approach and
meta-regression. Stat Med. 21:589–624. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Copas J and Shi JQ: Meta-analysis, funnel
plots and sensitivity analysis. Biostatistics. 1:247–262. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Egger M, Smith Davey G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
|
|
30
|
Ambe CM, Mahipal A, Fulp J, Chen L and
Malafa MP: Effect of metformin use on survival in resectable
pancreatic cancer: A single-institution experience and review of
the literature. PLoS One. 11:e01516322016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Choi Y, Kim TY, Oh DY, Lee KH, Han SW, Im
SA, Kim TY and Bang YJ: The impact of diabetes mellitus and
metformin treatment on survival of patients with advanced
pancreatic cancer undergoing chemotherapy. Cancer Res Treat.
48:171–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kozak MM, Anderson EM, von Eyben R, Pai
JS, Poultsides GA, Visser BC, Norton JA, Koong AC and Chang DT:
Statin and metformin use prolongs survival in patients with
resectable pancreatic cancer. Pancreas. 45:64–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan
M and Li D: Metformin use is associated with better survival of
diabetic patients with pancreatic cancer. Clin Cancer Res.
18:2905–2912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Amin S, Mhango G, Lin J, Aronson A,
Wisnivesky J, Boffetta P and Lucas AL: Metformin improves survival
in patients with pancreatic ductal adenocarcinoma and pre-existing
diabetes: A propensity score analysis. Am J Gastroenterol.
111:1350–1357. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chaiteerakij R, Petersen GM, Bamlet WR,
Chaffee KG, Zhen DB, Burch PA, Leof ER, Roberts LR and Oberg AL:
Metformin use and survival of patients with pancreatic cancer: A
cautionary lesson. J Clin Oncol. 34:1898–1904. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: A representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lu S and Archer MC: Sp1 coordinately
regulates de novo lipogenesis and proliferation in cancer cells.
Int J Cancer. 126:416–425. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nair V, Pathi S, Jutooru I, Sreevalsan S,
Basha R, Abdelrahim M, Samudio I and Safe S: Metformin inhibits
pancreatic cancer cell and tumor growth and downregulates Sp
transcription factors. Carcinogenesis. 34:2870–2879. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Y, Storr SJ, Johnson K, Green AR,
Rakha EA, Ellis IO, Morgan DA and Martin SG: Involvement of
metformin and AMPK in the radioresponse and prognosis of luminal
versus basal-like breast cancer treated with radiotherapy.
Oncotarget. 5:12936–12949. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lonardo E, Cioffi M, Sancho P,
Sanchez-Ripoll Y, Trabulo SM, Dorado J, Balic A, Hidalgo M and
Heeschen C: Metformin targets the metabolic achilles heel of human
pancreatic cancer stem cells. PLoS One. 8:e765182013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith
J and Rozengurt E: Different patterns of Akt and ERK feedback
activation in response to rapamycin, active-site mTOR inhibitors
and metformin in pancreatic cancer cells. PLoS One. 8:e572892013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
El-Mir MY, Nogueira V, Fontaine E, Avéret
N, Rigoulet M and Leverve X: Dimethylbiguanide inhibits cell
respiration via an indirect effect targeted on the respiratory
chain complex I. J Biol Chem. 275:223–228. 2000. View Article : Google Scholar : PubMed/NCBI
|
